Evidence map›Paper›PMID 20567520›Full record

ArticlePloS one2010

Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy?

Larisa C Lotoski, F Estelle R Simons, Rishma Chooniedass, Joel Liem, Isha Ostopowich, Allan B Becker, Kent T HayGlass

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Larisa C LotoskiDepartment of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada.
F Estelle R Simons
Rishma Chooniedass
Joel Liem
Isha Ostopowich
Allan B Becker
Kent T HayGlass
University of Manitoba · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundFood allergies are a major component of the burden of allergic disease. Accurate risk assessment for prediction of future clinical reactivity or clinical tolerance is limited by currently available techniques. Recent studies suggest that constitutively elevated global serum levels of IL-10, a cytokine that down-regulates both Th1 and Th2 cytokine production, may be useful in identifying human clinical tolerance to foods.

objectiveDetermine the usefulness of constitutive IL-10 levels as a marker of clinical tolerance to peanut in children and adults. METHODOLOGY/PRINCIPAL

findings107 subjects who were clinically tolerant to peanut and 94 subjects who were clinically allergic to peanut participated. Plasma was analyzed via ELISA to quantify the frequency of individuals with constitutive IL-10 levels and the intensity of those responses. The data were then stratified by age, gender and clinical status to assess the utility of this putative biomarker in specific at-risk groups. All 201 subjects had readily quantified plasma IL-10. Levels were no higher in subjects who were clinically tolerant to peanut than those in individuals clinically allergic to peanut. Stratification by age, gender or both did not improve the capacity of IL-10 levels to identify clinical tolerance to peanut. CONCLUSIONS/SIGNIFICANCE: Plasma IL-10 levels are neither a useful biomarker of clinical tolerance to peanut nor a potential tool for identification of clinical tolerance to peanut in humans.

Indexed as

Immune ToleranceAdolescentAdultCase-Control StudiesChildEnzyme-Linked Immunosorbent AssayHumansInterleukin-10Middle AgedPeanut HypersensitivityYoung AdultInterleukin-10

Identifiers

PMID20567520
PMCPMC2887371
OpenAlexW2005787997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.